[go: up one dir, main page]

PE20010545A1 - USE OF A COMPOSITION OF MEK INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN - Google Patents

USE OF A COMPOSITION OF MEK INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN

Info

Publication number
PE20010545A1
PE20010545A1 PE2000000705A PE0007052000A PE20010545A1 PE 20010545 A1 PE20010545 A1 PE 20010545A1 PE 2000000705 A PE2000000705 A PE 2000000705A PE 0007052000 A PE0007052000 A PE 0007052000A PE 20010545 A1 PE20010545 A1 PE 20010545A1
Authority
PE
Peru
Prior art keywords
alkyl
composition
treatment
pain
chronic pain
Prior art date
Application number
PE2000000705A
Other languages
Spanish (es)
Inventor
Kevin Lee
Alistair Dixon
Robert Denham Pinnock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20010545A1 publication Critical patent/PE20010545A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)

Abstract

SE REFIERE AL USO DE UNA COMPOSICION QUE COMPRENDE UN INHIBIDOR DE MEK TAL COMO DERIVADOS DEL ACIDO 4-BROMO Y 4-YODO FENILAMINOBENZHIDROXAMICO, DONDE R1 ES H, OH, ALQUILO C1-C8, ALCOXI C1-C8, HALO, TRIFLUOROMETILO, CN; R2 ES H; R3, R4, R5 SON H, OH, HALO, TRIFLUOROMETILO, ALQUILO C1-C8, ENTRE OTROS; n ES 0-4; m ES 0-1; R10 Y R11 SON H, ALQUILO C1-C8, JUNTO CON N FORMAN UN CICLO DE 3-10 MIEMBROS; R6 ES H, ALQUILO C1-C8, ENTRE OTROS; R7 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS; R6 Y R7 JUNTO CON N-O FORMAN UN CICLO DE 5-10 MIEMBROS. SON COMPUESTOS I PREFERIDOS 4-FLUORO-N-HIDROXI-2-(4-YODO-2-METIL-FENILAMINO)-BENZAMIDA, 3,4-DIFLUORO-2-(4-YODO-2-METIL-FENILAMINO)-N-(3-FURILMETOXI)BENZAMIDA, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE DOLOR CRONICO (DOLOR NEUROPATICO, DOLOR IDIOPATICO, DOLOR ASOCIADO AL ALCOHOLISMO CRONICO, DEFICIENCIA VITAMINICA, UREMIA, HIPOTIROIDISMOREFERS TO THE USE OF A COMPOSITION THAT INCLUDES A MEK INHIBITOR SUCH AS DERIVATIVES OF 4-BROMINE AND 4-IODINE PHENYLAMINOBENZHYDROXAMIC ACID, WHERE R1 IS H, OH, C1-C8 ALKYL, C1-C8 ALCOXY, HALOME, TRIFLUHYL, HALOMETHYL R2 IS H; R3, R4, R5 ARE H, OH, HALO, TRIFLUOROMETHYL, C1-C8 ALKYL, AMONG OTHERS; n IS 0-4; m IS 0-1; R10 AND R11 ARE H, C1-C8 ALKYL, TOGETHER WITH N, FORM A CYCLE OF 3-10 MEMBERS; R6 IS H, C1-C8 ALKYL, AMONG OTHERS; R7 IS H, C1-C8 ALKYL, C2-C8 ALKYL, AMONG OTHERS; R6 AND R7 TOGETHER WITH N-O FORM A CYCLE OF 5-10 MEMBERS. PREFERRED I COMPOUNDS ARE 4-FLUORO-N-HYDROXY-2- (4-IODO-2-METHYL-PHENYLAMINE) -BENZAMIDE, 3,4-DIFLUORO-2- (4-IODO-2-METHYL-PHENYLAMINE) -N- (3-FURILMETOXI) BENZAMIDE, AMONG OTHERS. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF CHRONIC PAIN (NEUROPATHIC PAIN, IDIOPATIC PAIN, PAIN ASSOCIATED WITH CHRONIC ALCOHOLISM, VITAMIN DEFICIENCY, UREMIA, HYPOTHYROIDISM

PE2000000705A 1999-07-16 2000-07-14 USE OF A COMPOSITION OF MEK INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN PE20010545A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16

Publications (1)

Publication Number Publication Date
PE20010545A1 true PE20010545A1 (en) 2001-06-04

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000705A PE20010545A1 (en) 1999-07-16 2000-07-14 USE OF A COMPOSITION OF MEK INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN

Country Status (16)

Country Link
EP (1) EP1202726A2 (en)
JP (1) JP2003504400A (en)
KR (1) KR20020012315A (en)
CN (1) CN1373660A (en)
AR (1) AR024732A1 (en)
AU (1) AU5786000A (en)
CA (1) CA2374052A1 (en)
CO (1) CO5300398A1 (en)
HU (1) HUP0202623A3 (en)
IL (1) IL147619A0 (en)
NZ (1) NZ515567A (en)
PE (1) PE20010545A1 (en)
PL (1) PL352684A1 (en)
TR (1) TR200200082T2 (en)
WO (1) WO2001005392A2 (en)
ZA (1) ZA200109907B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1219753C (en) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 Oxygenated esters of 4-iodoanilinophenylhydroxamic acid
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
IL163995A0 (en) 2002-03-13 2005-12-18 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
JPWO2005035493A1 (en) * 2003-10-08 2006-12-21 帝人ファーマ株式会社 Process for producing aminopyrrolidine derivative and intermediate compound
RU2352558C2 (en) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Polymorphic form of n-[(r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide
WO2005051300A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
PH12012501891A1 (en) 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EP1967516B1 (en) 2005-05-18 2009-11-04 Array Biopharma, Inc. 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases
CA2622755C (en) 2005-10-07 2017-01-31 Exelixis, Inc. Azetidines as mek inhibitors
DK2054418T3 (en) 2006-07-06 2012-02-27 Array Biopharma Inc Dihydrothienopyrimidines as AKT protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
SI2049500T1 (en) 2006-07-06 2012-01-31 Array Biopharma Inc CYCLOPENTA ?áD?å PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS
EP2101759B1 (en) 2006-12-14 2018-10-10 Exelixis, Inc. Methods of using mek inhibitors
MX2009014013A (en) 2007-07-05 2010-01-28 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors.
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ582692A (en) 2007-07-05 2012-05-25 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN101868443A (en) * 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-phenyl anthranilic acid derivatives and uses thereof
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
ES2422733T3 (en) 2008-01-09 2013-09-13 Array Biopharma Inc Hydroxylated pyrimidylcyclopentanes as AKT protein kinase inhibitors
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
PL2531502T3 (en) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EP2632899A1 (en) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Substituted phenoxypyridines
WO2012135779A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt and mek inhibitor compounds, and methods of use
BR112013025353A8 (en) 2011-04-01 2018-01-02 Genentech Inc combination of a) a compound of formula ia, compound of formula ia or a pharmaceutically acceptable salt thereof, method for treating a hyperproliferative disorder in a mammal, use of a compound of formula ia or a pharmaceutically acceptable salt thereof, kit and product
GEP201706690B (en) 2012-10-12 2017-06-26 Exelixis Inc Novel process for making compounds for use in treatment of cancer
US11465978B2 (en) 2013-09-11 2022-10-11 The Administrators Of The Tulane Educational Fund Anthranilic amides and the use thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
JP7080812B2 (en) 2015-10-27 2022-06-06 アセチロン ファーマシューティカルズ インコーポレイテッド HDAC inhibitors for the treatment of diabetic peripheral neuropathy
EP3973960B1 (en) 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
AU2020306249B2 (en) * 2019-06-28 2025-06-26 University Of Copenhagen Treatment of CNS disorders with sleep disturbances

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
ES2229515T3 (en) * 1997-07-01 2005-04-16 Warner-Lambert Company Llc 4-BROMO OR 4-IODINE DERIVATIVES OF BENZHYDROXAMIC PHENYLAMINE ACID AND ITS USE AS INHIBITORS OF THE MEK.
CA2290509A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
CA2346448A1 (en) * 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors

Also Published As

Publication number Publication date
HUP0202623A3 (en) 2003-03-28
HUP0202623A2 (en) 2002-11-28
AU5786000A (en) 2001-02-05
WO2001005392A2 (en) 2001-01-25
PL352684A1 (en) 2003-09-08
ZA200109907B (en) 2003-02-28
IL147619A0 (en) 2002-08-14
WO2001005392A3 (en) 2001-07-19
KR20020012315A (en) 2002-02-15
EP1202726A2 (en) 2002-05-08
CN1373660A (en) 2002-10-09
NZ515567A (en) 2004-03-26
TR200200082T2 (en) 2002-04-22
CA2374052A1 (en) 2001-01-25
CO5300398A1 (en) 2003-07-31
AR024732A1 (en) 2002-10-23
JP2003504400A (en) 2003-02-04

Similar Documents

Publication Publication Date Title
PE20010545A1 (en) USE OF A COMPOSITION OF MEK INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN
PE20010547A1 (en) USE OF A MEK INHIBITOR COMPOSITION TO TREAT CHRONIC PAIN
PE20020693A1 (en) PEROXISOMAS PROLIFERATOR AGONISTS OF THE ACTIVATED ALPHA RECEPTOR
AR097445A2 (en) OXYGEN ESTERS OF BENZHYDROXAMIC 4-IODINE PHENYLAMINE ACIDS
PE20020220A1 (en) DIPEPTIDE NITRILE COMPOUNDS AS CATEPSIN K INHIBITORS
FI822943L (en) TROMBOX SYNTHETIC INHIBITOR, PROCESSER FOR FRAMSTAELLNING AND PHARMACEUTICAL COMPOSITION INNEHAOLLANDE DESSA
CO5070574A1 (en) DERIVED FROM PHENOXYACETIC ACID AND PHARMACEUTICAL COMPOSITION CONTAINING IT
DK187186A (en) N-INDOLYLETHYL-SULPHONIC ACID AMIDES, THEIR PREPARATION AND USE
PE16299A1 (en) 2-IMIDAZOLINYLAMINOINDOL COMPOUNDS USEFUL AS ALPHA-2 ADRENORECEPTOR AGONISTS
KR950702655A (en) Novel 3-substituted para-aminophenols and use therof in dyeing keratinous fibres
PE20030924A1 (en) COMBINATION OF PTM INHIBITORS OR INHIBITORS OF APOB SECRETION WITH FIBRATES FOR USE AS MEDICINES
ES429234A1 (en) N-(1-({107 -phenyl-alkyl)-piperidyl-4)-N-({60 -pyridyl)-carboxylic acid amides and salts thereof
MY102219A (en) Leukotriene antagonists
ES477421A1 (en) Omega-(2-(N-lower alkyl-benzamido)-phenyl)-alkanoic acids, their use and preparation, and medicaments containing them.
EP0235452A3 (en) Organic compounds and their pharmaceutical use
CO5700781A2 (en) DOPAMINE MORPHOLINIC AGONISTS
DE3864660D1 (en) Thiophen-derivate.
TR200202439T2 (en) Sodium hydrogen exchanger type 1 inhibitor (NHE-1)
ES454668A1 (en) PROCEDURE FOR THE PREPARATION OF NEW HOMOPHTHALIMIDES.
GB1185334A (en) Thienobenzothiazepines
ZA839552B (en) Optionally active phenoxypropionic acid derivatives
DK0740657T3 (en) 4-Arylisoindoles with analgesic effect
CO5130024A1 (en) DERIVATIVES OF AZABICICLOHEPTANO N-SUBSTITUTES. .
DK102084D0 (en) N- (3-TRIFLUORMETHYLPHENYL) -N'-PROPARGYLPIPERAZINE, ITS PREPARATION AND USE
AR035585A1 (en) DERIVATIVES OF ACID 2-AMINO-2-ALQUIL-4-HEPTENOICO, PHARMACEUTICAL COMPOSITION AND ITS USE IN THE MANUFACTURE OF MEDICINES

Legal Events

Date Code Title Description
FC Refusal